Head and Neck Squamous Cell Carcinoma
Clinical research in metastatic and unresectable recurrent HNSCC focuses on immunotherapy-based combinations and first-line treatment settings for advanced disease.
- Pembrolizumab
- Platinum-based chemotherapy
- Objective response rate
The sponsor’s work in this area centers on treatment options for patients with advanced disease who have not yet received therapy for their metastatic or recurrent cancer.
HER2-Positive Breast Cancer
Research in metastatic HER2-positive breast cancer examines anti-HER2 regimens in patients with HER2 copy number amplification detected in circulating tumour DNA.
- Trastuzumab
- Single-agent chemotherapy
- Circulating tumour DNA
This therapeutic area reflects interest in biomarker-defined breast cancer populations with advanced metastatic disease.
HER2-Overexpressing Gastric and Gastroesophageal Junction Adenocarcinoma
Clinical studies address advanced gastric cancer and gastroesophageal junction adenocarcinoma after prior HER2-directed therapy and chemotherapy, with emphasis on later-line treatment strategies.
- Ramucirumab
- Paclitaxel
- Overall survival
These trials focus on patients whose disease has progressed following earlier HER2-targeted and cytotoxic treatment.
Myelodysplastic Syndromes
Research in higher-risk myelodysplastic syndrome includes both newly diagnosed and relapsed or refractory disease, with attention to patients requiring disease-modifying treatment.
- Azacitidine
- Complete response
- Higher-risk MDS
The sponsor is active in hematologic malignancy research involving treatment combinations for bone marrow failure and clonal blood disorders.
